公司治理越来越导向狭隘财务指标，如季度盈利等，制药公司不断提高 药价，而NHS 承担了成本。
With corporate governance increasingly oriented around narrow financial indicators such as quarterly earnings, drug companies have hiked up medicine prices, and the NHS is bearing the costs.